[Clinical tolerance of CY 216 (Fraxiparin) in the prevention of thromboembolic accidents after neurosurgery].
Clinical tolerance of CY 216 was assessed on 97 patients in two neurosurgical departments (Hopital Lariboisière and Hopital Beaujon, Paris). All the 97 patients were operated on by different cranial approaches, but always including bone flap. No thrombo-embolic event could be detected in this series. Post-operative intracranial hemorrhage was observed in 19 cases on the basis of CT scan performed on the first and seventh post-operative day. Among these 19 patients, 8 presented an increase of the hemorrhagic aspect between the 2 CT scan. However, clinical state of these patients improved and no reoperation was necessary to treat these hemorrhages. From this study, we consider that CY 216 is an effective mean of thrombo-embolism prevention with little hemorrhagic side-effect. Therefore, it can be recommended in the aftermath of intracranial surgical procedures.